Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic benefits in cases of CML which were found to be resistant to treatment with imatinib (Gleevec), anoth...
For the potential treatment of various leukemias, including chronic myeloid leukemia (CML).
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.